Full-Time

Strategic Account Manager

Medical Communications

Precision AQ

Precision AQ

501-1,000 employees

Data-driven drug access and launches

Compensation Overview

$79.4k - $119k/yr

Remote in USA

Remote

Remote within the United States.

Bachelor's, PharmD, PhD, MD

Category
Sales & Account Management (1)
Required Skills
Market Research
Sales
Computer Networking
Business Strategy

Get referred to Precision AQ

See people who can refer or advise you

Requirements
  • Bachelor’s degree required
  • Minimum of 3 years of experience in account management, overseeing both client relationships and internal teams within the medical communications or a related industry
Responsibilities
  • Understand the business challenges your client is facing and what strategic questions they are or should be asking
  • Help clients define and achieve their business goals
  • Prepare annual strategic/tactical plans for each client and individual campaign/project plans as needed throughout the year
  • Manage and strengthen client relationships
  • Propose, sell to clients, and oversee ideas and projects that are tied to clients’ objectives
  • Continuously offer unsolicited ideas to increase the effectiveness of clients’ brand and company activities
  • Understand revenue generation and recognition, and contribute to Precision AQ’s profitability through good management
  • Serve as an advocate and strong representative for Precision AQ
  • Identify and cultivate new business opportunities (even if it means just passing them along internally)
  • Initiate and oversee Precision AQ activities on behalf of and in support of clients
  • Manage day-to-day client-Precision AQ communication on strategy (ideas, recommendations, approaches to consider) and planning
  • Become a partner to each client, functioning as an extension of the client’s team by taking ownership and accountability for their business
  • Closely manage clients’ budget and team efficiency to maximize return for clients and Precision AQ
  • Work with the internal team to exceed clients’ expectations
  • Mentor, train, and coach team members to facilitate growth and development
  • Stay abreast of developments (eg, science, competitors, regulations) in clients’ industries
  • Keep honing marketing and strategy expertise to better serve clients and Precision AQ
  • Network and connect to grow your influence and add value
  • _support of the StrAcctDir may include tasks such as: assisting in the preparation of annual strategic/tactical plans for clients and Precision AQ, addressing ad hoc client requests and needs, reviewing and finalizing materials for distribution to the client or other external parties, participating in and/or leading calls with clients or healthcare practitioners, preparing content as necessary to fulfill client requirements, traveling to and attending and supporting live meetings with clients and/or healthcare practitioners, and more. The day-to-day activities of a SAM will vary greatly depending on client needs, account size, product status, and Precision AQ needs and may include assuming an independent lead role on individual projects as well as responsibility for a modest revenue goal.
Desired Qualifications
  • Advanced degree (PhD, MD or PharmD) in life sciences, pharmacy, medicine, and/or advanced degree in management, marketing or business is preferred
  • Prior exposure to medical affairs, publications, and/or peer-to-peer marketing is strongly preferred
  • PowerPoint design proficiency
  • Strong strategic and analytical background
  • Ability to interact in a professional manner with clients and leaders with scope in a variety of therapeutic areas
  • Ability to understand and interpret market dynamics, scientific information, and clinical and preclinical data
  • Ability to interpret business metrics and financial information
  • Resourcefulness, tenacity, independence, energy, and self-confidence

Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

New York City, New York

Founded

N/A

Get referred to Precision AQ

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Precision AQ says it serves all 30 top pharma companies and launched 450-plus drugs.
  • April 25, 2025 oncology hires sharpen payer, provider, and formulary strategy for launches.
  • May 28, 2026 ASCO materials showcase OncoGenius and Navigator365 Matrix with 100-plus cancer centers.

What critics are saying

  • IQVIA, ICON, and Syneos Health crowd Precision AQ’s commercialization niche globally.
  • AI patient-services commoditization from Phluence-style tools compresses consulting margins by 2027.
  • Reliance on pharma launch budgets creates existential exposure if one major client insources access strategy.

What makes Precision AQ unique

  • Precision AQ’s AET has 25-plus former access decision-makers, built since 2009.
  • February 17, 2026 hires Emma Hawe and Yahya Anvar deepen HEOR, AI, and EU reach.
  • November 18, 2025 Phluence investment extends agentic post-Rx automation beyond traditional HUB models.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Parental Leave

Performance Bonus

Company News

PR Newswire
Feb 17th, 2026
Precision AQ expands leadership with AI and data strategy hires to strengthen global biopharma solutions

Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.

StreetInsider
Nov 18th, 2025
Precision AQ Invests in Phluence Platform

Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.

PR Newswire
Apr 25th, 2025
Precision Aq Expands Industry-Leading Access Experience Team (Aet) With Three Oncology Experts

-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S

PR Newswire
Mar 31st, 2025
Precision Aq Earns Hitrust Implemented, 1-Year I1 Certification For Data Protection And Cybersecurity Risk Management

HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls

GlobeNewswire
Mar 4th, 2025
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...